north40000, thanks for your observations today. There seems to be some dissonance between the value of Bavi+chemo and Bavi in immuno combinations. I have read and appreciated CP’s opinion on the subject, to which you have pointed.
My view is that there is considerable value in each, but considerably more in both, for interesting reasons.
I see more than one geographical market to consider. You remind us:
“Remember Dr. G's words to us at the PPHM ASM 2014. 500,000 pages had already been submitted to FDA.”
If Dr. Garnick is successful in his efforts with respect to the BLA, Bavituximab will be on the path to its first FDA approval...second line NSCLC.
This would mean mega manufacturing at Avid, and entry into a worldwide market.
Since Bavituximab is ready to move into I-O combination trials through current collaborations with MSK, NCCN, and AstraZeneca, new Bavi revenues and further partnering for those trials would quickly start to accelerate, and drive toward I-O combo fruition.
My preference is to see oncology move rapidly into I-O combinations where we are likely to see more remissions, adaptive immunities and some full cures for cancer patients.
But there is also a near to midterm need for cancer treatments that are affordable, and therefor available to patients in the second and third world. As patents run out in the years ahead, I-O should become more widely available in all markets.
The dissonance that I referred to, comes from the potential threat in the first world of an FDA approved Bavi+Doce combo that could under price and over perform early I-O combinations. This is a bit of a conundrum.
There is a whole lot of leverage for a Peregrine that controls a safe and efficacious FDA approved Bavi+chemo combo for this first lung cancer indication.
Leverage is not a bad thing to have in your back pocket.
But, again, the downside is the repression of this safe and efficacious cancer treatment to the entire, rapidly developing I-O market, and to Peregrine’s own I-O combination efforts.
It’s sorta like an “embarrassment of riches”. Peregrine could hardly be expected to suppress its Bavi+Doce potential, because of its current development stage as a small biotech. If it were already a fully fledged BP with deep pockets, and on the road to developing major I-O candidates it might be a tad less stressful and less dissonant to set the chemo options aside.
Putting a whole new twist on “We live in interesting times.”
Market Data 
Markets 
AI
